1356332-28-9 Usage
General Description
2,3-di-p-tolyl-5,6,7,8-tetrahydropyrido[2,3-b]pyrazine is a chemical compound with a complex structure. It belongs to the class of pyrido[2,3-b]pyrazine derivatives and is characterized by the presence of four p-tolyl groups and a tetrahydropyrido ring system. 2,3-di-p-tolyl-5,6,7,8-tetrahydropyrido[2,3-b]pyrazine has potential applications in medicinal chemistry and pharmaceutical research due to its unique structure and potential biological activities. It may also be used as a building block in organic synthesis to create other related compounds with desired properties. However, this particular compound may also have hazardous effects and should be handled with caution in laboratory settings.
Check Digit Verification of cas no
The CAS Registry Mumber 1356332-28-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,5,6,3,3 and 2 respectively; the second part has 2 digits, 2 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1356332-28:
(9*1)+(8*3)+(7*5)+(6*6)+(5*3)+(4*3)+(3*2)+(2*2)+(1*8)=149
149 % 10 = 9
So 1356332-28-9 is a valid CAS Registry Number.
1356332-28-9Relevant articles and documents
SALTS OF AN IP RECEPTOR AGONIST
-
Page/Page column 30; 31, (2013/07/25)
The invention relates to salts of (7-(2,3-di-p-tolyl-7,8-dihydropyrido[2,3-b]pyrazin-5(6H)- yl)heptanoic acid which are useful for treating diseases affected by the activation of the IP receptor, pharmaceutical compositions that contain the salts and processes for preparing the salts are also described.
FUSED PIPERIDINES AS IP RECEPTOR AGONISTS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) AND RELATED DISORDERS
-
Page/Page column 62, (2013/07/25)
The present invention provides heterocyclic derivatives which activate the IP receptor, processes for preparing them, pharmaceutical compositions comprising said derivatives and uses thereof. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients. Formula (I):
